Valuation: Cartesian Therapeutics, Inc.

Market Cap 187M 167M 154M 140M 262M 17.75B 266M 1.86B 734M 9.29B 702M 687M 29.32B P/E 2026 *
-2.06x
P/E 2027 * -1.49x
Enterprise Value 45.98M 41.05M 37.89M 34.38M 64.39M 4.37B 65.37M 456M 181M 2.28B 173M 169M 7.21B EV / Sales 2026 *
110x
EV / Sales 2027 * -360x
Free-Float
47.87%
Yield 2026 *
-
Yield 2027 * -
1 day-3.59%
1 week-1.44%
Current month-14.29%
1 month-18.90%
3 months-21.57%
6 months-8.44%
Current year-14.29%
1 week 6.01
Extreme 6.01
6.71
1 month 6.01
Extreme 6.01
8.05
Current year 5.6
Extreme 5.6
11
1 year 5.6
Extreme 5.6
11
3 years 5.6
Extreme 5.6
42.6
5 years 5.6
Extreme 5.6
42.6
10 years 5.6
Extreme 5.6
42.6
Date Insider Type Main position Quantity % Market Cap. Importance
4/2/26 Exercice 758,001 2.8594%
4/2/26 Exercice 22,740 --
4/2/26 Exercice 22,740 --
Change 5-day change 1-year change 3-year change Capi.($)
-3.59%-1.44%-32.53% - 187M
+2.41%+0.29%+42.02%+71.57% 64.69B
-0.15%+7.50%+11.42%+71.27% 54.78B
+0.57%+4.60%+7.71%+90.93% 53.49B
+0.37%+4.67%+26.68%+49.64% 45.98B
-1.21%+2.32%+21.50%+118.33% 42.94B
-0.37%+5.07%+243.23%+789.58% 40.08B
+0.05%+0.21%+18.26%+58.53% 33.52B
-0.38%+5.68%+38.39%+28.35% 23.67B
+1.19%-4.98%+26.31%-0.76% 23.97B
Average -0.11%+2.03%+40.30%+141.94% 38.33B
Weighted average by Cap. +0.39%+2.73%+46.44%+143.62%

Financials

2026 *2027 *
Net sales 419K 374K 345K 313K 587K 39.79M 596K 4.16M 1.65M 20.83M 1.57M 1.54M 65.73M 286K 255K 235K 214K 400K 27.13M 406K 2.84M 1.12M 14.2M 1.07M 1.05M 44.8M
Net income -88.41M -78.93M -72.86M -66.12M -124M -8.39B -126M -877M -347M -4.39B -332M -325M -13.86B -144M -129M -119M -108M -202M -13.67B -205M -1.43B -565M -7.16B -540M -529M -22.58B
Net Debt -141M -126M -116M -105M -197M -13.39B -200M -1.4B -554M -7.01B -529M -518M -22.11B -290M -259M -239M -217M -406M -27.5B -412M -2.87B -1.14B -14.39B -1.09B -1.06B -45.43B
Projected Income Statement - Annual - Cartesian Therapeutics, Inc.
Logo Cartesian Therapeutics, Inc.
Cartesian Therapeutics, Inc. is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. It leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. The Company’s lead asset, Descartes-08, is a chimeric antigen receptor T-cell therapy (CAR-T) entering Phase 3 clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-B-cell maturation antigen (BCMA) CAR-T being evaluated in a Phase 1 trial in patients with multiple myeloma. Descartes-08 is an autologous chimeric antigen receptor T-cell therapy product targeting B-cell maturation antigen in clinical development for generalized myasthenia gravis and systemic lupus erythematosus.
Employees
75
Date Price Change Volume
26-10-23 US$6.180 -3.59% 85,901
26-10-22 US$6.410 -0.16% 89,200
26-10-21 US$6.420 +0.39% 105,973
26-10-20 US$6.395 +5.18% 168,585
26-10-19 US$6.080 -3.03% 201,517
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Cartesian Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
6.180USD
Average target price
33.67USD
Spread / Average Target
+444.77%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Cartesian Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. RNAC Stock